Introduction
============

According to the Punjab cancer registry report, acute lymphoblastic leukemia (ALL) is a predominant malignancy among children and it makes up most prevalent cancer in Punjab, Pakistan. The worldwide incidence rate is 1--4.75 per 100,000 people. In Pakistan ALL contributes to 17.9% of all cancers. It is characterized by mutation in blast cells in hematopoietic stem cells, spleen, neurons, gonads, lymph nodes, and hepatic cells ([@ref-25]). Although, B-ALL is very common in children but it may also occur in the adult populace ([@ref-12]). Several demographic parameters like gender, age, family history and biological factors also play an important role in the prevalence of disease. Other factors like exposure to UV, radiations, lifestyle may also act as risk factors ([@ref-21]; [@ref-1]). Mutation in certain genes involved in different processes like apoptosis, proliferation and differentiation of B-cells may also cause B-ALL. These genetic alterations largely affect the prediction and therapeutic approach used for medication and therapy of ALL ([@ref-38]).

FMS-like tyrosine kinase (*FLT3*) belongs to class III receptor tyrosine kinase (RTK) family. Structurally, *FLT3* consists of an extracellular domain at the amino terminus. This domain comprises of immunoglobulin-like transmembrane region and intracellular juxta-membrane domain (JMD). At the carboxyl terminus, there are two kinase domains, separated by a kinase insert region ([@ref-16]). *FLT3* is expressed in normal human bone marrow especially in CD34+ hematopoietic stem, brain ([@ref-7]) and gonads ([@ref-23]; [@ref-35]) and encodes 1,000 amino acid protein in humans. In the hematopoietic tissues, binding of FL with its receptor causes auto-phosphorylation of tyrosine residues present in the kinase domain and stimulates growth of progenitor cells in the marrow and blood ([@ref-22]). This results in downstream activation of signaling pathways that are involved in regulation of cell cycle or apoptosis, including (PI3K), caspase-9 and Ras/Raf pathways and causes multiplied proliferation of cells, reduced cell apoptosis, and inhibition of B-cell differentiation ([@ref-43]).

In hematologic malignancy, 70% to 100% increased expression of *FLT3* in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) is reported previously ([@ref-6]; [@ref-17]). Rosnet and colleagues reported that three out of five ALL subjects with increased expression of *FLT3* in leukemia blasts ([@ref-29]). Another study showed that up regulation of *FLT3* gene is a potential risk factor of leukemia ([@ref-9]).

B-cell-specific activator protein (*PAX5*) encodes transcription factors that are the member of a paired box domain. *PAX5* plays imperative role in the commitment of B-cell lineage from blast cells as it controls the differentiation of a pro-B cell to pre-B cells ([@ref-14]; [@ref-20]). In pre-pro-B cells the immunoglobin gene rearrangement starts and matures into pro-B cells. Expression of PAX5 gene initiates from pro-B stage and terminates at pre-B stage. In late B-lymphoposis, PAX5 maintains the function of mature B-cells ([@ref-32]).

In B-cell malignancies, *PAX5* act as an oncogene. Down-regulation of *PAX5* halts B-cells and reverts B-cell precursors (BCPs) to progenitors (pro B-cell stage) ([@ref-31]; [@ref-8]). Conversely, uncontrolled proliferation of the B-cells leads to the abnormal expression of *PAX5* in precursor cells and inhibit T-cell proliferation ([@ref-36]). It is reported that in childhood ALL, translocations and mutation in *PAX5* are more prevalent ([@ref-5]; [@ref-24]; [@ref-30]; [@ref-18]). Alternative splicing of *PAX5* in exon 7 to exon 9 results into five isoforms. These isoforms are more expressed in primary B-cell lymphoma tissues and cancerous cell lines ([@ref-45]; [@ref-2]).

Previous studies showed that the presence of single nucleotide polymorphisms (SNPs) in genome maybe risk causing or protective for the disease and it may also alters the pharmacokinetic and pharmacodynamics properties of drugs ([@ref-19]; [@ref-26]; [@ref-38]). We selected two non-synonomous SNPs including 13q12.2 ([rs35958982](http://www.ncbi.nlm.nih.gov/snp/?term=rs35958982), *FLT3*), 557 (Val \> Ile) at position Chr13:28034336 (GRCh38.p12) and 9p13.2 ([rs3780135](http://www.ncbi.nlm.nih.gov/snp/?term=rs3780135), *PAX5*), 293 (Thr \> Ile) at position Chr9:36840626 (GRCh38.p12). A synonomous SNP 13q12.2 ([rs12430881](http://www.ncbi.nlm.nih.gov/snp/?term=rs12430881), *FLT3*), (A \> G) at position Chr13:28020665 (GRCh38.p12) was also selected. The change in amino acid sequence due to non-synonomous SNP alters the protein structure implicating its expression and function. Current study is designed to evaluate the role of *FLT3* and *PAX5* genes in B-cell lymphoblastic leukemia. For this purpose, a case control analysis was conducted to evaluate the polymorphic association of [rs35958982](http://www.ncbi.nlm.nih.gov/snp/?term=rs35958982), [rs3780135](http://www.ncbi.nlm.nih.gov/snp/?term=rs3780135) and [rs12430881](http://www.ncbi.nlm.nih.gov/snp/?term=rs12430881) with B-cell acute lymphoblastic leukemia (B-ALL) incidence.

Materials & Methods
===================

Study subjects
--------------

The present study was conducted at the University of Punjab, Pakistan and granted ethical approval to carry out the study within its facilities (Ethical Application Ref: sbs/222/18). Blood samples were collected during the period of January 2017 to February 2017 from Children's Hospital, Lahore, Pakistan. Study population comprised of 155 cases and 155 controls younger than 15 years of age. The diagnostic criteria for B-ALL cases include B-cell positive markers (CD19, CD10, CD22, and CD20) confirmed by flow cytometry analysis. Cases with relapsed and newly diagnosed B-ALL were also included. All 310 subjects recruited were consented to participate in this study after filling the questionnaire. The subjects with any other type of leukemia, blood infectious disease, and B-ALL subjects older than 15 years of age were excluded from the study. Family history with cancer, parental consanguinity (first and second degree relatives) and smoking status (\>100 cigarettes in lifetime) were gathered by questionnaire interviewed.

Genotyping
----------

Venous blood samples of cases and controls were collected in EDTA vials. DNA extraction was done using Sam brook 2001 organic protocol. The genes and SNPs associated with B-ALL were screened using DisGeNET platform ([@ref-27]) and were verified by dbSNP database ([@ref-33]). Presence of the selected SNPs in Pakistani population was confirmed by Ensembl genome browser ([@ref-42]). In order to identify the SNPs, tetra arm primers were designed using Primer1 software ([@ref-41]) as shown in [Table 1](#table-1){ref-type="table"}. Tetra arms PCR was done using advanced primus 96 (PeqLab) thermal cycler ([Table 2](#table-2){ref-type="table"}). PCR products were further analyzed by gel electrophoresis ([Figs. 1](#fig-1){ref-type="fig"}--[3](#fig-3){ref-type="fig"}).
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###### Tetra-ARMS primers.
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  Primer                                                           Sequence (5′--3′)           Tm (°C)
  ---------------------------------------------------------------- --------------------------- ---------
  [rs35958982](http://www.ncbi.nlm.nih.gov/snp/?term=rs35958982)   TGTGACAAATTAGCAGGGTTAACAC   57.3
  CACAGAAGAGATCACAGAAGGAGTCT                                       60.7                        
  GAAACTCCCATTTGAGATCATATTCA                                       56.0                        
  AGACAGAGACAAGCAGACATTCG                                          58.4                        
  [rs3780135](http://www.ncbi.nlm.nih.gov/snp/?term=rs3780135)     CTCTTCCAGGCTCCCCCGAC        59.2
  GGGCGGCAGCGCTATAAGAA                                             59.5                        
  ACCCCAGCTCTAGATGGCGAAG                                           56.6                        
  ATAGGTGCCATCAGTGTTTGGTGC                                         58.4                        
  [rs12430881](http://www.ncbi.nlm.nih.gov/snp/?term=rs12430881)   GTTTGTCTCCTCTTCATTGGCA      56.0
  GCCTCAGTGTCATCTTCGAATT                                           56.3                        
  CCTTTTATCTTCACATCAGGCCT                                          56.6                        
  CTTAGTAGAGATGGGGTTTTGCC                                          58.4                        
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###### PCR program for SNPs.
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  PCR steps                                                                  Temperature (°C)   Duration of steps   No. of cycles
  -------------------------------------------------------------------------- ------------------ ------------------- ---------------
  Initial duration                                                           92                 5 min               30--35
  Denaturation                                                               94                 30 sec              
  Annealing [rs35958982](http://www.ncbi.nlm.nih.gov/snp/?term=rs35958982)   58.4               1 min               
  [rs3780135](http://www.ncbi.nlm.nih.gov/snp/?term=rs3780135)               56.6                                   
  [rs12430881](http://www.ncbi.nlm.nih.gov/snp/?term=rs12430881)             58.8                                   
  Extension                                                                  72                 1 min               
  Final extension                                                            72                 5 min               

![SNP [rs35958982](http://www.ncbi.nlm.nih.gov/snp/?term=rs35958982).\
Well 1 indicates the DNA ladder (100 bp), an amplicon (395 bp) is outer band. Amplicon 272 bp: allele 'A' and amplicon of 170 bp allele 'G'.](peerj-07-7195-g001){#fig-1}

![SNP [rs3780135](http://www.ncbi.nlm.nih.gov/snp/?term=rs3780135).\
Well 1 indicates the DNA ladder (50 bp), an amplicon (331 bp) is outer band. Amplicon 243 bp: allele 'A' and amplicon of 128 bp: allele 'G'.](peerj-07-7195-g002){#fig-2}

![SNP [rs12430881](http://www.ncbi.nlm.nih.gov/snp/?term=rs12430881).\
Well 1 indicates the DNA ladder (100 bp), an amplicon (400 bp) is outer band. Amplicon 165 bp: allele G and amplicon of 280 bp: allele A.](peerj-07-7195-g003){#fig-3}

Statistical analysis
--------------------

Statistical studies were performed using IBM SPSS 23. Chi-square test was conducted to compare categorical data. Allele and genotype association between SNPs and B-ALL were calculated by computing odds ratio (OR) and 95% confidence interval (CI). The Bonferroni corrections were applied for all multiple tests. A logistic regression model was used to adjust different B-ALL risk factors. The probability level accepted for significance was *P* \< 0.05.

Results
=======

Family history of cancer and parental consanguinity showed significant association with B-ALL while, there was no association with the smoker parents. Subjects with a family history of any type of cancer showed a high risk of having B-ALL (OR = 15.42, *P* = 0.000). Previous studies showed smoking as a risk factor for cancer but our cohort displayed a contradictory results as no significant association was found in B-ALL subjects (OR = 0.85, *P* = 0.580). In the present study, more B-ALL subjects were product of parental consanguinity and showed highly significant association with the risk of B-ALL (OR = 1.87, *P* = 0.050) ([Table 3](#table-3){ref-type="table"}).

Our data showed that none of the subjects and their parents was exposed to radiations. Furthermore, 18 patients had liver hepatomegaly sized 11.7 ± 3.3 mm, nine cases had nephropathy of right kidney 9.47 ± 2.9 mm and left kidney 10.01 ± 2.3 mm. Symptoms like night sweating, dizziness, abdominal pain, vomiting, bruises, pallor, enlarged lymph nodes, cough with blood, loose stools, jaundice, pedal edema, pain, dehydration, hepatosplenomegaly, atypical blast cells mild abdominal ascites, low leukocytes and thrombocytopenia were also recorded.

In our cohort, [rs35958982](http://www.ncbi.nlm.nih.gov/snp/?term=rs35958982) encoding isloleucine form of codon frequency in subjects was 13.4% and 5.6% in controls. Moreover, statistical analysis showed positive association of allele frequency (OR = 2.30, CI \[1.20--4.50\], *P* = 0.005) and no association of genotype frequency (OR = 3.67, CI \[0.75--18.10\], *P* = 0.088) with the disease. Another polymorphism [rs3780135](http://www.ncbi.nlm.nih.gov/snp/?term=rs3780135), a minor allele frequency in subjects was 47.1% and 32.58% in controls showing positive association with B-ALL (OR = 2.17, CI \[1.37--3.43\], *P* = 0.000). The genotype frequency showed protective effect with B-ALL (OR = 0.55, CI \[0.72--1.83\], *P* = 0.029). The SNP [rs12430881](http://www.ncbi.nlm.nih.gov/snp/?term=rs12430881) allele frequency (OR = 1.15, CI \[1.37--3.43\], *P* = 0.043) and genotype frequency (OR = 2.52, CI \[1.28--4.95\], *P* = 0.006) showed strong association with the disease as shown in [Table 4](#table-4){ref-type="table"}. After applying Bonferroni correction, SNPs [rs35958982](http://www.ncbi.nlm.nih.gov/snp/?term=rs35958982), [rs3780135](http://www.ncbi.nlm.nih.gov/snp/?term=rs3780135) and [rs12430881](http://www.ncbi.nlm.nih.gov/snp/?term=rs12430881) remained statistically significant and showed *P*-value 0.030, 0.010 and 0.002 respectively.

Multivariate regression analysis was performed after adjusting the baseline for conventional B-ALL risk factors such as family history, smoking and parental consanguinity. As shown in [Table 4](#table-4){ref-type="table"}, the multivariate analysis indicated that outcome of heterozygous genotype GA in SNPs [rs35958982](http://www.ncbi.nlm.nih.gov/snp/?term=rs35958982), [rs3780135](http://www.ncbi.nlm.nih.gov/snp/?term=rs3780135) and [rs12430881](http://www.ncbi.nlm.nih.gov/snp/?term=rs12430881) had significant association with B-ALL and showed odds ratio (OR = 1.13, CI \[0.41--3.08\]), (OR = 1.19, CI \[0.52--2.73\]) and (OR = 1.09, CI \[0.48--2.69\]) respectively. Additionally, risk genotypes in SNPs [rs35958982](http://www.ncbi.nlm.nih.gov/snp/?term=rs35958982) (AA) and [rs12430881](http://www.ncbi.nlm.nih.gov/snp/?term=rs12430881) (GG) showed positive association with disease having an odds ratio (OD = 1.30, CI \[0.37--5.08\]) and (OD = 1.03, CI \[0.50--2.68\]), respectively. However, the risk genotype (AA) of SNP [rs3780135](http://www.ncbi.nlm.nih.gov/snp/?term=rs3780135) displayed no association with B-ALL after adjusting for environmental factors. Stratification analysis of environmental factors showed smoking as major risk factor in both heterozygous and risk genotype of SNP [rs3780135](http://www.ncbi.nlm.nih.gov/snp/?term=rs3780135) and [rs12430881](http://www.ncbi.nlm.nih.gov/snp/?term=rs12430881) whereas, parental consanguinity act as risk factor only in heterozygous genotype of SNP [rs3780135](http://www.ncbi.nlm.nih.gov/snp/?term=rs3780135) as shown in [Table 5](#table-5){ref-type="table"}.
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###### Association of demographic factors with risk of B-ALL.
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  Parameters                  Patients (%)   Control (%)   Odd ratio   Chi-square   *P* value
  --------------------------- -------------- ------------- ----------- ------------ -----------------------------------------
  Age (mean)                  7.30           11.70                                  
  A positive family history   16.77          1.29          15.42       14.59        0.000[^\*^](#table-3fn1){ref-type="fn"}
  A negative family history   83.22          98.70                                  
  Smoking by parent           38.06          41.94         0.85        0.31         0.580
  No smoking parent           61.93          58.06                                  
  Parental cousin marriage    33.55          21.29         1.87        3.78         0.050[^\*^](#table-3fn1){ref-type="fn"}
  No cousin marriage          66.45          78.70                                  
  Females                     56             72            0.65        3.41         0.070
  Males                       99             83                                     

**Notes.**

Significant values are shown in (\*).
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###### Allele and genotype frequency.

Adjusted ORs were obtained from logistic regression model with adjustment for family history, smoking and consanguinity.
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  Gene/SNP                                                         Allele/ Genotype   Controls (%)   Cases (%)           Crude OR (95% CI)   Adjusted OR (95% CI)   *χ*^2^   [^a^](#table-4fn1){ref-type="fn"}*P*-value   [^b^](#table-4fn2){ref-type="fn"}*P*-value
  ---------------------------------------------------------------- ------------------ -------------- ------------------- ------------------- ---------------------- -------- -------------------------------------------- --------------------------------------------
  [rs35958982](http://www.ncbi.nlm.nih.gov/snp/?term=rs35958982)   Allele                                                                                                                                                 
                                                                   A                  5.60           13.40               2.30 (1.20-4.50)    --                     7.79     0.005\*                                      0.002\*
                                                                   G                  94.40          86.60               --                                                                                               
                                                                   Genotype                                                                                                                                               
                                                                   GG                 90.70          79.60               3.67 (0.75-18.10)   1.00                   2.90     0.088                                        0.030\*
                                                                   GA                 7.60           13.80                                   1.13 (0.41--3.08)                                                            
  AA                                                               1.85               6.50           1.30 (0.37--5.08)                                                                                                    
  [rs3780135](http://www.ncbi.nlm.nih.gov/snp/?term=rs3780135)     Allele                                                                                                                                                 
                                                                   A                  32.58          47.10               2.17 (1.37-3.43)    --                     13.63    0.000\*                                      0.000\*
                                                                   G                  67.42          52.90               --                                                                                               
                                                                   Genotype                                                                                                                                               
                                                                   GG                 52.26          33.55               0.55 (0.39-0.95)    1.00                   4.72     0.029\*                                      0.010\*
                                                                   GA                 30.32          38.70                                   1.19 (0.52--2.73)                                                            
  AA                                                               17.42              27.74          0.97 (0.26--1.42)                                                                                                    
  [rs12430881](http://www.ncbi.nlm.nih.gov/snp/?term=rs12430881)   Allele                                                                                                                                                 
                                                                   G                  22             29                  1.15 (0.72-1.83)    --                     4.11     0.043\*                                      0.014\*
                                                                   A                  78             71                  --                                                                                               
                                                                   Genotype                                                                                                                                               
                                                                   AA                 65.16          61.93               2.52 (1.28 -4.95)   1.00                   7.51     0.006\*                                      0.002\*
                                                                   GA                 25.80          18.06                                   1.09 (0.48--2.69)                                                            
  GG                                                               9.03               20             1.03 (0.50--2.68)                                                                                                    

**Notes.**

Critical *P* value.

Bonferroni corrected *P* value.

Significant values are shown in (\*).

10.7717/peerj.7195/table-5

###### Stratification analysis for association between genotypes and risk of B-ALL.

ORs were obtained from logistic regression model with adjustment for family history, smoking and consanguinity.
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                                                                       **OR (95% CI)**                      
  -------------------------------------------------------------------- ----------------- ------------------ ------------------
  **[rs35958982](http://www.ncbi.nlm.nih.gov/snp/?term=rs35958982)**   **GG**            **GA**             **AA**
  Family history status                                                                                     
  Yes                                                                  1                 0.92(0.18--4.56)   0.50(0.06--4.15)
  No                                                                                                        
  Smoking status                                                                                            
  Yes                                                                  1                 0.30(0.08--1.09)   0.46(0.10--2.12)
  No                                                                                                        
  Consanguinity status                                                                                      
  Yes                                                                  1                 0.86(0.24--3.10)   0.94(0.20--4.37)
  No                                                                                                        
  **[rs3780135](http://www.ncbi.nlm.nih.gov/snp/?term=rs3780135)**     **GG**            **GA**             **AA**
  Family history status                                                                                     
  Yes                                                                  1                 0.60(1.70--0.21)   0.44(0.15--1.30)
  No                                                                                                        
  Smoking status                                                                                            
  Yes                                                                  1                 1.08(0.46--2.50)   1.3(0.59--2.90)
  No                                                                                                        
  Consanguinity status                                                                                      
  Yes                                                                  1                 0.62(0.26--1.44)   0.60(0.26--1.35)
  No                                                                                                        
  **[rs12430881](http://www.ncbi.nlm.nih.gov/snp/?term=rs12430881)**   **AA**            **AG**             **GG**
  Family history status                                                                                     
  Yes                                                                  1                 0.58(0.16--2.15)   1.80(0.65--4.98)
  No                                                                                                        
  Smoking status                                                                                            
  Yes                                                                  1                 1.05(0.45--2.42)   1.08(0.45--2.60)
  No                                                                                                        
  Consanguinity status                                                                                      
  Yes                                                                  1                 1.15(0.50--2.65)   0.49(0.18--1.35)
  No                                                                                                        

Discussion
==========

According to previous studies, association of first and second degree family history of cancer signifies genetic and environmental risk factor for causing acute lymphoblastic leukemia. Our study also showed positive association of family history with B-ALL (OR = 15.42, *P* = 0.000). Earlier, parental smoking has also been associated with the prevalence of ALL but our study showed contrary results (OR = 0.85, *P* = 0.580) ([@ref-3]). Parental consanguinity is still practiced in Pakistan, which results in minor allele pool and contributes to the occurrence of disease. Our results are in accordance with ([@ref-37]; [@ref-39]) which states that familial occurrence of leukemia exists (OR = 1.87, *P* = 0.050). Some studies found a correlation between parental exposure to radiation before conception, that may be due to their working environment ([@ref-34]). In our analysis, neither patients nor parents were ever exposed to radiations. Hepatomegaly and nephropathy are often seen in B-ALL subjects having chemotherapy. Malfunctioned leucocytes in the liver and kidney leads to enlargement of these organs ([@ref-28]). Another study suggests that hepatomegaly and nephropathy may be the consequence of chemotherapeutic toxicity ([@ref-15]).

It is well established fact that cancer risk is influenced by numerous genetic variants having any risk or protective effect. The degree of penetrance of a certain genotype in the population and environmental factors is a major cause of cancer ([@ref-11]). The information given by allelic and genotypic data of single nucleotide polymorphism in a population propose the possible genetic markers for cancer risk and predict possible targeted therapies ([@ref-17]; [@ref-40]).

In this study, SNP [rs35958982](http://www.ncbi.nlm.nih.gov/snp/?term=rs35958982) is a germline polymorphism present in transmembrane region of *FLT3* gene. It is a non-synonymous variant which leads to the change in structure of the protein. High throughput DNA sequence analysis has been done to check the frequency of [rs35958982](http://www.ncbi.nlm.nih.gov/snp/?term=rs35958982) with leukemiogenesis in drivers and passengers which showed no association with AML ([@ref-13]). Present study in contrast displayed the association of SNP [rs35958982](http://www.ncbi.nlm.nih.gov/snp/?term=rs35958982) with the disease (OR = 2.30, CI \[1.20--4.50\], *P* = 0.005). Detailed analysis of genotype frequency in the population showed no association with B-ALL (OR = 3.67, CI \[0.75--18.10\], *P* = 0.088). This might be due to the fact that SNP [rs35958982](http://www.ncbi.nlm.nih.gov/snp/?term=rs35958982) is rare in acute lymphoblastic leukemia with low penetrance. Current study also depicts that individuals with risk allele A at locus 13q12.2 ([rs12430881](http://www.ncbi.nlm.nih.gov/snp/?term=rs12430881), *FLT3*) (OR = 1.15, CI \[1.37--3.43\], *P* = 0.0426) and genotype GG were more prone to B-ALL (OR = 2.52, CI \[1.28--4.95\], *P* = 0.006). It has been found that disruption of *FLT3* gene due to the presence of mutation or SNP leads to deficiency of B-lymphoid progenitors suggesting its critical role in survival and proliferation of blast cells ([@ref-44]).

[@ref-4] studied allele frequency of paired box domain (*PAX5*) polymorphism [rs3780135](http://www.ncbi.nlm.nih.gov/snp/?term=rs3780135) in different populations, i.e., African 34%, African European 49%, Central Asian 85%, East Asian 94%, European 95% and Hispanic 88%. Pakistan lies in South East Asia having frequency of [rs3780135](http://www.ncbi.nlm.nih.gov/snp/?term=rs3780135) (47.1%) which is lower than previously reported in East Asian population. [@ref-10] found polymorphism [rs3780135](http://www.ncbi.nlm.nih.gov/snp/?term=rs3780135) in B-ALL subjects with increased mRNA expression of *PAX5* suggesting the possible role of SNP with increased proliferation of blast cells. In Pakistani population, minor allele frequency was significantly identified in B-ALL subjects (OR = 2.17, CI \[1.37--3.43\], *P* = 0.000). Heterozygous genotype GA (38.7%) was more frequently identified in our cohort than homozygous risk genotype AA (27.74%) which manifested significant difference in frequency (CI \[0.72--1.83\], *P* = 0.029) and also showed protective effect (OR = 0.55). *PAX5* is involved in repression of T-cells, activation of B-cell proliferation from blast cell therefore, presence of any variant in this gene affects its pathway which may leads to increased expression of *PAX5* and results into B-ALL ([@ref-10]).

Conclusions
===========

The findings of the present study significantly demonstrate that SNPs [rs35958982](http://www.ncbi.nlm.nih.gov/snp/?term=rs35958982) and [rs12430881](http://www.ncbi.nlm.nih.gov/snp/?term=rs12430881) correlate with the increase risk of B-ALL, however, SNP [rs3780135](http://www.ncbi.nlm.nih.gov/snp/?term=rs3780135) has a protective effect. The environmental risk factors of B-ALL, including family history, parental consanguinity and smoking, are found to have an imperative role in progression of disease. Although the data is balanced, but not robust, the small cohort of subjects limits the conclusion of article. To eliminate this limitation and validate the results of present study, larger prospective studies need to be conducted in the same ethnic group. Furthermore, various other demographic and environmental factors should also be considered and appraised for their association with B-ALL.
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###### Raw data

Raw data showing genotype of 3 SNPs and environmental factors associated with the disease. Sheet 1 displays patients data and sheet 2 display controls data.
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Click here for additional data file.
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